BIOLINERX     Print Page  Close Window

SEC filings
SC 13G/A
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP filed this Form SC 13G/A on 02/16/2016
Entire Document
 
 

 

CUSIP No. 09071M106
 SCHEDULE 13G/A
Page 2 of 8 Pages
         
1
NAME OF REPORTING PERSONS
 
OrbiMed Israel BioFund GP Limited Partnership
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
2,638,600 (1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
2,638,600 (1)
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,638,600 (1)
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
4.69% (2)
12
TYPE OF REPORTING PERSON
 
PN
(1) Evidenced by 1,038,600 American Depositary Shares ("ADS") (each ADS represents one Ordinary Shares (as defined below)) and 1,600,000 ADSs issuable upon the exercise of warrants to purchase ADSs (the "Warrants") held by OrbiMed Partners (as defined below).
(2) This percentage is based upon 54,654,811 Ordinary Shares outstanding as of October 15, 2015, as disclosed in the Issuer's Form F-3 filed with the Securities and Exchange Commission on October 16, 2015, and includes 1,600,000 ADSs issuable upon the exercise of warrants to purchase ADSs.